INmune Bio Establishes $65 Million At-The-Market Offering

The latest update is out from Inmune Bio ( (INMB) ).

On December 19, 2025, INmune Bio Inc. entered into a sales agreement with A.G.P./Alliance Global Partners, allowing the company to sell up to $65 million of its common stock from time to time through at-the-market offerings under an existing shelf registration. The company is not obligated to issue any shares, but A.G.P. will act as sales agent subject to customary conditions, earning a 3% commission on gross proceeds and receiving indemnification, contribution rights, and expense reimbursements, providing INmune Bio with flexible access to additional capital that could support its operational and development needs while potentially diluting existing shareholders over time.

The most recent analyst rating on (INMB) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Inmune Bio stock, see the INMB Stock Forecast page.

Spark’s Take on INMB Stock

According to Spark, TipRanks’ AI Analyst, INMB is a Neutral.

Inmune Bio’s overall stock score is hindered by significant financial challenges, including declining revenue and ongoing losses. While technical analysis shows mixed signals, valuation metrics suggest overvaluation. Positive corporate events and earnings call highlights provide some optimism, but financial instability and operational challenges remain key risks.

To see Spark’s full report on INMB stock, click here.

More about Inmune Bio

INmune Bio Inc. is a biotechnology company focused on developing immunotherapies, with its primary activities centered on advancing clinical-stage treatments that leverage the immune system to target disease, and it is listed on the Nasdaq Capital Market.

Average Trading Volume: 417,238

Technical Sentiment Signal: Sell

Current Market Cap: $48.65M

See more data about INMB stock on TipRanks’ Stock Analysis page.